Bintai Kinden partner to develop China's li-Key Covid-19 vaccine

KUALA LUMPUR: Bintai Kinden Corp bhd's partner Generex Biotechnology Corporation has entered a framework agreement with Chinese agencies to develop and commercialise a coronavirus vaccine in China.

It said in a statement issued today that Generex had entered the agreement with China Center for Disease Control and Prevention, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.